Sol-Gel Technologies Gross Profit 2016-2024 | SLGL
Sol-Gel Technologies gross profit from 2016 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Sol-Gel Technologies Annual Gross Profit
(Millions of US $) |
| 2023 |
$2 |
| 2022 |
$4 |
| 2021 |
$31 |
| 2020 |
$9 |
| 2019 |
$23 |
| 2018 |
$0 |
| 2017 |
$0 |
| 2016 |
$ |
| 2015 |
$ |
Sol-Gel Technologies Quarterly Gross Profit
(Millions of US $) |
| 2024-06-30 |
$5 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$0 |
| 2023-09-30 |
$0 |
| 2023-06-30 |
$1 |
| 2023-03-31 |
$0 |
| 2022-12-31 |
$0 |
| 2022-09-30 |
$0 |
| 2022-06-30 |
$4 |
| 2022-03-31 |
$0 |
| 2021-12-31 |
$21 |
| 2021-09-30 |
$9 |
| 2021-06-30 |
$1 |
| 2021-03-31 |
$1 |
| 2020-12-31 |
$2 |
| 2020-09-30 |
$2 |
| 2020-06-30 |
$1 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$4 |
| 2019-09-30 |
$5 |
| 2019-06-30 |
$8 |
| 2019-03-31 |
$6 |
| 2018-12-31 |
$-0 |
| 2018-09-30 |
$0 |
| 2018-06-30 |
$0 |
| 2018-03-31 |
$0 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.014B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
